Seattle Genetics’ Adcetris gets FDA priority review for Hodgkin lymphoma

This article was originally published here

The US Food and Drug Administration (FDA) has granted priority review to a Seattle Genetics’ supplemental biologics license application (BLA) that seeks approval of (brentuximab vedotin) in combination with chemotherapy in combination with chemotherapy for the frontline treatment of advanced classical Hodgkin lymphoma.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply